A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
NCT00551850
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Cancer
Refractory Cancer
Interventions
DRUG:
AV-412
Sponsor
AVEO Pharmaceuticals, Inc.